Drug Profile


Alternative Names: MT 5199; NBI-98854; VMAT2 inhibitor - Neurocrine Biosciences

Latest Information Update: 31 Jan 2017

Price : $50

At a glance

  • Originator Neurocrine Biosciences
  • Developer Mitsubishi Tanabe Pharma Corporation; Neurocrine Biosciences
  • Class 3-ring heterocyclic compounds; Amino acids; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Drug-induced dyskinesia
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Drug-induced dyskinesia
  • Phase II Gilles de la Tourette's syndrome
  • Phase I Huntington's disease
  • No development reported Schizophrenia

Most Recent Events

  • 17 Jan 2017 Top-line efficacy results from a phase II trial in Gilles de la Tourette's syndrome reported by Neurocrine Biosciences
  • 17 Jan 2017 Neurocrine Biosciences completes the T-FORWARD phase II trial for Gilles de la Tourette's Syndrome in USA (PO)
  • 05 Jan 2017 US FDA cancelled the Psychopharmacologic Drugs Advisory Committee meeting which was previously scheduled to happen in February 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top